Acid sphingomyelinase is a gatekeeper of placental labyrinthine architecture and function
Development · 2025
DOI: 10.1242/dev.204425 ↗Kurz gefasst
Fachartikel in der Zeitschrift Development, 2025. Verfasst von Isidora Rovic und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Physiology, Temerty Faculty of Medicine, University of Toronto, Toronto, Ontario M5S 1A8, Canada. Hauptthemen laut MEDLINE: Sphingomyelin Phosphodiesterase, Placenta. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Natural Sciences and Engineering Research Council of Canada, CIHR, Canadian Institutes of Health Research.
Abstract (Originalsprache)
Sphingolipids are a class of bioactive signaling lipids that regulate an array of fundamental cellular processes, including cell survival, proliferation and differentiation. Deficiency of acid sphingomyelinase – an enzyme of the sphingolipid metabolic pathway – has been previously implicated in human placental pathologies. We demonstrate that acid sphingomyelinase (Smpd1) is required for normal placental development in the mouse, and its deficiency results in an intrauterine growth restriction phenotype. Smpd1-deficient placentas display several anatomical abnormalities, including a reduced labyrinth compartment and increased fetal-maternal interhaemal distance. Finally, we observed several hallmarks of defective autophagy and lysosomal impairment in Smpd1−/− placentas, which could explain the inability of Smpd1−/− trophoblast to respond to nutrient starvation. Fetal growth restriction could not be rescued by transfer of Smpd1-deficient embryos into a wild-type uterine environment; however, restoration of transcription factor EB phosphorylation was detected. Thus, we conclude that, due to a smaller labyrinthine area, Smpd1 deficiency leads to a decrease in exchange between maternal and fetal blood space, limiting the supply of nutrients to the fetus and resulting in growth restriction.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Physiology, Temerty Faculty of Medicine, University of Toronto, Toronto, Ontario M5S 1A8, Canada.
- Lunenfeld-Tanenbaum Research Institute, Sinai Health System, Toronto, Ontario M5G 1X5, Canada.
- Mouse Imaging Centre, 25 Orde Street, Toronto, Ontario M5T 3H7, Canada.
- Translational Medicine, Hospital for Sick Children, Toronto, Ontario M5G 0A4, Canada.
- Department of Medical Biophysics, University Health Network-Toronto General Hospital, Toronto, Ontario M5G 1L7, Canada.
- Department of Obstetrics and Gynecology, Temerty Faculty of Medicine, University of Toronto, Toronto, Ontario M5G 1E2, Canada.
ORCID-Profile: Andrea Jurisicova
Förderung
- Natural Sciences and Engineering Research Council of Canada
- CIHR
- Canadian Institutes of Health Research
Zitieren
APA
Rovic, I., Szelag, K., Li, H., McQuaid, R., Sugin, S., Wu, Q., Theodora, N., Sled, J., & Jurisicova, A. (2025). Acid sphingomyelinase is a gatekeeper of placental labyrinthine architecture and function. Development. https://doi.org/10.1242/dev.204425
Vancouver
Rovic I, Szelag K, Li H, McQuaid R, Sugin S, Wu Q, et al. Acid sphingomyelinase is a gatekeeper of placental labyrinthine architecture and function. Development. 2025. doi:10.1242/dev.204425
BibTeX
@article{Rovic2025,
author = {Rovic, Isidora and Szelag, Katherine and Li, Han and McQuaid, Rosanne and Sugin, Sara and Wu, Que and Theodora, Natalia and Sled, John and Jurisicova, Andrea},
title = {Acid sphingomyelinase is a gatekeeper of placental labyrinthine architecture and function},
journal = {Development},
year = {2025},
doi = {10.1242/dev.204425}
}
EUVIMED